These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34334296)

  • 1. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
    Manglaviti S; Brambilla M; Signorelli D; Ferrara R; Lo Russo G; Proto C; Galli G; De Toma A; Occhipinti M; Viscardi G; Beninato T; Zattarin E; Bini M; Lobefaro R; Massa G; Bottiglieri A; Apollonio G; Sottotetti E; Di Mauro RM; Trevisan B; Ganzinelli M; Fabbri A; de Braud FGM; Garassino MC; Prelaj A
    Clin Lung Cancer; 2022 Jan; 23(1):e17-e28. PubMed ID: 34334296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis.
    Miyashita K; Karayama M; Inoue Y; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kono M; Matsui T; Niwa M; Koda K; Toyoshima M; Matsushima S; Matsuura S; Asada K; Fujii M; Kusagaya H; Matsuda H; Inui N; Suda T
    BMC Pulm Med; 2021 Oct; 21(1):309. PubMed ID: 34600514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety analysis of immunotherapy in non-small cell lung cancer patients with MET alterations.
    Wang Y; Wei J; Xu M; Xiang J; Shao K; Hao Y; Song Z
    Clin Transl Oncol; 2024 Oct; 26(10):2503-2512. PubMed ID: 38627317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio.
    Bongiovanni A; Foca F; Menis J; Stucci SL; Artioli F; Guadalupi V; Forcignanò MR; Fantini M; Recine F; Mercatali L; Spadazzi C; Burgio MA; Fausti V; Miserocchi A; Ibrahim T
    Front Immunol; 2021; 12():697298. PubMed ID: 34858389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
    Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
    Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy.
    Lefebvre C; Martin E; Hendriks LEL; Veillon R; Puisset F; Mezquita L; Ferrara R; Sabatier M; Filleron T; Dingemans AC; Besse B; Raherisson C; Mazières J
    Respir Med Res; 2020 Nov; 78():100788. PubMed ID: 32980653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High bone tumor burden to identify advanced non-small cell lung cancer patients with survival benefit upon bone targeted agents and immune checkpoint inhibitors.
    Manglaviti S; Bini M; Apollonio G; Zecca E; Galli G; Sangaletti S; Labianca A; Sottotetti E; Brambilla M; Occhipinti M; Proto C; Prelaj A; Signorelli D; De Toma A; Viscardi G; Beninato T; Mazzeo L; Bottiglieri A; Leporati R; Fotia G; Ganzinelli M; Portararo P; Garassino MC; de Braud FGM; Lo Russo G; Torri V; Ferrara R
    Lung Cancer; 2023 Dec; 186():107417. PubMed ID: 37918061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
    Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
    Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
    BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of primary cancer adjoining emphysematous bullae in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Takamori S; Takada K; Shimokawa M; Jinnnouchi M; Matsubara T; Haratake N; Miura N; Toyozawa R; Yamaguchi M; Takenoyama M; Yoneshima Y; Tanaka K; Okamoto I; Tagawa T; Mori M
    Cancer Immunol Immunother; 2021 Jun; 70(6):1745-1753. PubMed ID: 33389013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
    Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G
    Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC.
    Mao S; Zhou F; Liu Y; Yang S; Chen B; Xu J; Wu F; Li X; Zhao C; Wang W; Liu Q; Yu X; Jia K; Shao C; Zhou C; Gao G; Ren S
    Cancer Immunol Immunother; 2022 Jan; 71(1):219-228. PubMed ID: 34097116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC).
    Xu Z; Li T; Hu X; Hao X; Xing P; Li J
    Thorac Cancer; 2021 Sep; 12(17):2360-2368. PubMed ID: 34268872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non-small cell lung cancer.
    Zhao Q; Li B; Xu Y; Wang S; Zou B; Yu J; Wang L
    Cancer Med; 2021 Sep; 10(18):6291-6303. PubMed ID: 34390218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.